➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKesson
Johnson and Johnson
Baxter
Medtronic

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 5,543,316

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,543,316
Title: Injectable culture medium for maintaining viability of myoblast cells
Abstract:An injectable grade medium for maintaining cells comprising: (a) a sugar; (b) a serum albumin; (c) a calcium salt; (d) a phosphate salt; (e) a source of iron; (f) at least one salt of a Group I element; (g) at least one salt of a Group II element; (h) at least one amino acid; and (i) at least one vitamin. Components (a) through (i) are present in the medium in amounts in order to provide an osmolality of the medium of from about 320 mOsm/kg to about 550 mOsm/kg. Such an injectable grade medium has an increased osmolality as compared with conventional media, and thus such medium may be employed in order to maintain cells over extended periods of time and for injecting such cells into a desired transplantation site of a patient, whereby such cells are transplanted into the patient, and are capable of functioning in the patient.
Inventor(s): Zawadzka; Agatha (Charlestown, MA), Tsang; Wen-Ghih (Lexington, MA), Brown; Robert H. (Needham, MA)
Assignee: Diacrin, Inc. (Charlestown, MA) The General Hospital Corporation (Boston, MA)
Application Number:08/230,334
Patent Claims:see list of patent claims

Details for Patent 5,543,316

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Grifols Usa, Llc PLASBUMIN albumin (human) SOLUTION 101138 1 1994-09-26   Start Trial Diacrin, Inc. (Charlestown, MA) The General Hospital Corporation (Boston, MA) 2040-01-28 search
Baxalta Us Inc. FLEXBUMIN albumin human INJECTION, SOLUTION 101452 1 2014-07-31   Start Trial Diacrin, Inc. (Charlestown, MA) The General Hospital Corporation (Boston, MA) 2040-01-28 search
Csl Behring Ag ALBURX albumin (human) SOLUTION 102366 1 2009-01-06   Start Trial Diacrin, Inc. (Charlestown, MA) The General Hospital Corporation (Boston, MA) 2040-01-28 search
Grifols Usa, Llc ALBUTEIN albumin (human) INJECTION, SOLUTION 102478 1 2019-12-15   Start Trial Diacrin, Inc. (Charlestown, MA) The General Hospital Corporation (Boston, MA) 2040-01-28 search
Grifols Usa, Llc HUMAN ALBUMIN GRIFOLS albumin (human) SOLUTION 103352 1 2003-06-11   Start Trial Diacrin, Inc. (Charlestown, MA) The General Hospital Corporation (Boston, MA) 2040-01-28 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Johnson and Johnson
Dow
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.